Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice

详细信息    查看全文

• 作者：S. J. van der Wall ; F. A. Klok ; P. L. den Exter ; D. Barrios ; R. Morillo ; S. C. Cannegieter ; D. Jimenez and M. V. Huisman
• 刊名：Journal of Thrombosis and Haemostasis
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：15
• 期：1
• 页码：74-79
• 全文大小：156K
• ISSN：1538-7836

文摘

Current guidelines recommend low-molecular-weight heparin (LMWH) monotherapy for 3–6 months as the first-line treatment for cancer-associated venous thromboembolism (VTE). However, although daily administration of LMWH injections over a course of several months may be burdensome, the number of patients who stop treatment because of LMWH side-effects is unknown.